%0 Figure %A Rébé, Cédric %A Filomenko, Rodolphe %A Raveneau, Magalie %A Chevriaux, Angélique %A Ishibashi, Minako %A Lagrost, Laurent %A Louis Junien, Jean %A Gambert, Philippe %A Masson, David %D 2012 %T Induction of LXR markers by T0901317 on CD14+ and CD14− cells among PBMCs. %U https://plos.figshare.com/articles/figure/_Induction_of_LXR_markers_by_T0901317_on_CD14_and_CD14_8722_cells_among_PBMCs_/208233 %R 10.1371/journal.pone.0048738.g004 %2 https://ndownloader.figshare.com/files/537750 %K lxr %K markers %K t0901317 %K cells %X

Isolated PBMCs were treated with DMSO or 10 µM T0901317 for 24 or 48 hours and CD226, CD244 or CD82 cell surface expression was evaluated by flow cytometry. A: Dot plot representing CD14− and CD14+ selected populations. B: CD226, CD244 or CD82 on CD14− cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments using cells from 4 distinct healthy donors. C: CD226, CD244 or CD82 on CD14+ cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments. Values are set at 1 in the DMSO conditions. * : significantly different from DMSO treatment (P<0.05 Wilcoxon T test). D: MFI in LXR agonist- and DMSO- treated PBMCswith or without 22-S-OH cholesterol added. Each bar is the mean ± S.E.M. of 3 independent experiments using CD14+ gated PBMCs from 3 distinct healthy donors. Values are set at 1 in the DMSO conditions. *: significantly different from DMSO treatment (P<0.05 Wilcoxon T test); †: significantly different from vehicle only conditions (P<0.05 Wilcoxon T test).

%I PLOS ONE